No photo of Richard A Bernstein

View Scopus Profile

Richard A Bernstein

  • 5916 Citations
1994 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Neurovascular Critical Care, Stroke, Stroke of unknown cause, stroke in young people, acute stroke therapy, atrial fibrillation, stem cell therapy for stroke.

Certifications and Licenses

Vascular Neurology
Neurology

Training Experience

1997Internship, Mount Sinai Hospital, Illinois
2000Residency, New York Presbyterian Hospital
2001Fellowship, Univ. of CA-San Francisco Med. Ctr.

Education/Academic qualification

MD, PhD, Cornell University Medical College

… → 1996

Research interests

  • Stroke

Fingerprint Dive into the research topics where Richard A Bernstein is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Stroke AF

Bernstein, R. A. & Caprio, F. Z.

Medtronic, Inc.

7/7/16 → 7/7/22

Project: Research project

Prot # 1160.129: Boehringer Ingelheim Pharmaceuticals, Inc., “GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation” (Phase II/III)

Bernstein, R. A.

Covance Inc., Boehringer Ingelheim Pharmaceuticals, Inc.

3/29/12 → 3/29/20

Project: Research project

Stroke Trials Network - Regional Coordinating Stroke Centers

Bernstein, R. A., Prabhakaran, S. & Roth, E. J.

National Institute of Neurological Disorders and Stroke

8/1/16 → 7/31/18

Project: Research project

Protocol #1160-189: Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, oral b.i.d.) Versus Acetylsalicylic Acid (100 mg oral q.d.) in

Bernstein, R. A. & Caprio, F. Z.

Boehringer Ingelheim Pharmaceuticals, Inc.

8/21/15 → 8/21/19

Project: Research project

A Phase III, Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0 g Idarucizumab (BI 655075) in Patients Treated with Dabigatran Etexilate who have Uncontrolled Bleeding or Require Emer

Bernstein, R. A.

Boehringer Ingelheim Pharmaceuticals, Inc.

4/6/15 → 4/6/18

Project: Research project

Research Output

Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups

Diener, H. C., Sacco, R. L., Easton, J. D., Granger, C. B., Bar, M., Bernstein, R. A., Brainin, M., Brueckmann, M., Cronin, L., Donnan, G., Gdovinová, Z., Grauer, C., Kleine, E., Kleinig, T. J., Lyrer, P., Martins, S., Meyerhoff, J., Milling, T., Pfeilschifter, W., Poli, S. & 4 others, Reif, M., Rose, D. Z., Šaňák, D. & Schäbitz, W. R., Jan 1 2020, (Accepted/In press) In : Stroke. p. 1758-1765 8 p.

Research output: Contribution to journal › Article

Open Access

    • The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants

    Hospital Quality Foundation, Jan 1 2020, (Accepted/In press) In : American Journal of Emergency Medicine.

    Research output: Contribution to journal › Comment/debate

    Open Access
    • 1 Scopus citations

    Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis

    Farrant, M., Easton, J. D., Adelman, E. E., Cucchiara, B. L., Barsan, W. G., Tillman, H. J., Elm, J. J., Kim, A. S., Lindblad, A. S., Palesch, Y. Y., Zhao, W., Pauls, K., Walsh, K. B., Martí-Fàbregas, J., Bernstein, R. A. & Johnston, S. C., Sep 4 2019, In : JAMA network open. 2, 9, p. e1910769

    Research output: Contribution to journal › Article

    Open Access

    • Dabigatran for prevention of stroke after embolic stroke of undetermined source

    Diener, H. C., Sacco, R. L., Donald Easton, J., Granger, C. B., Bernstein, R. A., Uchiyama, S., Kreuzer, J., Cronin, L., Cotton, D., Grauer, C., Brueckmann, M., Chernyatina, M., Donnan, G., Ferro, J. M., Grond, M., Kallmünzer, B., Krupinski, J., Lee, B. C., Lemmens, R., Masjuan, J. & 5 others, Odinak, M., Saver, J. L., Schellinger, P. D., Toni, D. & Toyoda, K., May 16 2019, In : New England Journal of Medicine. 380, 20, p. 1906-1917 12 p.

    Research output: Contribution to journal › Article

    • 84 Scopus citations

    Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

    on behalf of the EMPEROR-Reduced Trial Committees and Investigators, Executive Committee, National Coordinators, Consulting Statistician, Clinical Events Committee, Scientific Excellence Committee & Data Monitoring Committee, Oct 1 2019, In : European Journal of Heart Failure. 21, 10, p. 1270-1278 9 p.

    Research output: Contribution to journal › Article

    Open Access
    • 8 Scopus citations